Intracellular methicillin-resistant Staphylococcus aureus (MRSA) is extremely difficult to remove by common antibiotics, leading to infection recurrence and resistance. Herein we report a novel exosome-based antibiotic delivery platform for eradicating intracellular MRSA, where mannosylated exosome (MExos) is employed as the drug carrier and preferentially taken up by macrophages, delivering lysostaphin (MExoL) and vancomycin (MExoV) to intracellular pathogens. Combination of MExoL and MExoV eradicated intracellular quiescent MRSA. Moreover, MExos rapidly accumulated in mouse liver and spleen, the target organs of intracellular MRSA, after intravenous (IV) administration. Thus, the MExos antibiotic delivery platform is a promising strategy for combating intracellular infection.

细胞内耐甲氧西林的金黄色葡萄球菌（MRSA）很难用普通抗生素清除，导致感染复发和耐药。在本文中，我们报告了一种用于消灭细胞内MRSA的新型基于外泌体的抗生素递送平台，其中甘露糖基化的外泌体（MExos）被用作药物载体并优先被巨噬细胞吸收，将溶葡萄球菌素（MExoL）和万古霉素（MExoV）递送至细胞内病原体。MExoL和MExoV的结合消除了细胞内静态MRSA。而且，在静脉内（IV）给药后，MExos在小鼠肝脏和脾脏（细胞内MRSA的靶器官）中迅速积累。因此，MExos抗生素递送平台是对抗细胞内感染的一种有前途的策略。